Nintedanib improves progression-free survival in metastatic colorectal cancer
Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial presented ...
Oct 11, 2016